Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system disorders characterized by neuronal excitation-inhibition imbalance. The company offers cerebrum, a small molecule platform for CNS small molecule therapies and solidus, an antisense oligonucleotide platform to discover and develop antisense oligonucleotide. It is developing ulixacaltamide, a small molecule inhibitor of T-type calcium channels that is in Phase III clinical trial for the treatment of essential tremor; vormatrigine, a small molecule targeting the hyperexcitable state of sodium-channels in the brain to treat focal onset epilepsy; relutrigine for the treatment of developmental and epileptic encephalopathies; PRAX-020; and PRAX-050. In addition, the company develops elsunersen, a clinical-stage ASO designed to regulate NaV1.2 expression for the treatment of SCN2A-DEE; PRAX-080; PRAX-090; and PRAX-100. It has a license agreement with RogCon Inc.; and research collaboration and license agreement with Ionis Pharmaceuticals, Inc. The company was incorporated in 2015 and is based in Boston, Massachusetts.

Praxis Precision Medicines Inc.

Praxis Precision Medicines ( ($PRAX) ) just unveiled an announcement. On June 22, 2026, Praxis Precision Medicines, Inc. said the U.S. Food and Dru...

Praxis Wins FDA Breakthrough Status for Elsunersen Epilepsy Drug

An announcement from Praxis Precision Medicines ( ($PRAX) ) is now available. On June 10, 2026, Praxis Precision Medicines, Inc. held its 2026 Annu...

Praxis Precision Medicines Shareholders Back Directors and Governance

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Heron Therapeutics (HRTX) and Praxis Precision Medicines (PRAX). ...

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Heron Therapeutics (HRTX) and Praxis Precision Medicines (PRAX)

Truist Financial analyst Danielle Brill maintained a Buy rating on Praxis Precision Medicines today and set a price target of $616.00. According to...

Praxis Precision Medicines (PRAX) Gets a Buy from Truist Financial

In a report released today, Yasmeen Rahimi from Piper Sandler maintained a Buy rating on Praxis Precision Medicines, with a price target of $1,200....

Piper Sandler Remains a Buy on Praxis Precision Medicines (PRAX)

In a report released today, Francois Brisebois from LifeSci Capital reiterated a Buy rating on Praxis Precision Medicines, with a price target of $...

Praxis Precision Medicines (PRAX) Receives a Buy from LifeSci Capital

Praxis Precision Medicines ( ($PRAX) ) has issued an update. On June 1, 2026, Praxis Precision Medicines, Inc. reported topline results from its Ph...

Praxis Precision Reassesses Vormatrigine After Mixed POWER1 Data

Guggenheim analyst Yatin Suneja maintained a Buy rating on Praxis Precision Medicines yesterday and set a price target of $800.00. The company’s sh...

Guggenheim Remains a Buy on Praxis Precision Medicines (PRAX)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Praxis Precision Medicines (PRAX) and Eli Lilly & Co...

Current Yield	N/A	Payout Ratio	N/A
Annual DPS	$0.00	Growth Streak	0 years
Ex-Dividend	Invalid Date	Pay Date	Invalid Date
Record Date	N/A	Declaration	N/A
Frequency	NA	Quarterly Est	$0.00

	A	B	C	D
1	Symbol	Price	Change	Volume
2	PRAX	$303.39	+7.47%	641.20K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	PRAX	$303.39	+7.5%	641.20K
3
4
5
6

PRAX

PRAX

Dividend Overview

Get Praxis Precision Medicines Inc. Data in Excel

Get Praxis Precision Medicines Inc. Data in Excel